The medication improves glycaemic control through glucose-dependent insulin secretion and glucagon suppression
Community reports describe mild appetite changes, sleep disturbance, and increased resting heart rate in some users, but these are uncontrolled observations
This approach effectively removes barriers to treatment, promoting the wider adoption of GLP-1-based therapies within clinical practice
In a study in which juvenile dogs received lisdexamfetamine dimesylate for 6 months beginning at 10 weeks of age, decreased bodyweight gain was seen at all doses tested (2, 5, and 12 mg/kg/day, which are approximately 0.5, 1, and 3 times the maximum recommended human daily dose on a mg/m2 basis for a child)
1.5 Weight Loss Results / Efficacy 1.5 Weight Loss Results / Efficacy Expect about 35% weight loss in 12 weeks